172 related articles for article (PubMed ID: 29240604)
1. Potential Significance of Peptidome in Human Ovarian Cancer for Patients With Ascites.
Huang X; Zhou J; Tang R; Han S; Zhou X
Int J Gynecol Cancer; 2018 Feb; 28(2):355-362. PubMed ID: 29240604
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomic analysis of human malignant ascitic fluids for the development of gastric cancer biomarkers.
Jin J; Son M; Kim H; Kim H; Kong SH; Kim HK; Kim Y; Han D
Clin Biochem; 2018 Jun; 56():55-61. PubMed ID: 29654727
[TBL] [Abstract][Full Text] [Related]
3. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues.
Xu J; Wang X; Xu P; Liu S; Teng F; Liu X; Zhu Q; Hua X; Gong Z; Jia X
Int J Biochem Cell Biol; 2019 Feb; 107():53-61. PubMed ID: 30543932
[TBL] [Abstract][Full Text] [Related]
5. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
6. Role of malignant ascites on human mesothelial cells and their gene expression profiles.
Matte I; Lane D; Bachvarov D; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():288. PubMed ID: 24761768
[TBL] [Abstract][Full Text] [Related]
7. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analysis of Tumor-Associated microRNAs and Tetraspanines from Exosomes of Plasma and Ascitic Fluids of Ovarian Cancer Patients.
Yunusova N; Dzhugashvili E; Yalovaya A; Kolomiets L; Shefer A; Grigor'eva A; Tupikin A; Kondakova I; Tamkovich S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613908
[TBL] [Abstract][Full Text] [Related]
9. Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.
Miyamoto S; Ruhaak LR; Stroble C; Salemi MR; Phinney B; Lebrilla CB; Leiserowitz GS
J Proteome Res; 2016 Sep; 15(9):3358-76. PubMed ID: 27500424
[TBL] [Abstract][Full Text] [Related]
10. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
11. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle E; Taucher V; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
[TBL] [Abstract][Full Text] [Related]
12. [Ascites May Provide Useful Information for Diagnosis of Ovarian Cancer].
Stuchlíková E; Zahradníková M; Nenutil R; Valík D; Vojtěšek B; Novotný M; Hernychova L
Klin Onkol; 2017; 30(Supplementum1):187-190. PubMed ID: 28471203
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma.
Ho CM; Chang SF; Hsiao CC; Chien TY; Shih DT
J Biomed Sci; 2012 Feb; 19(1):23. PubMed ID: 22330345
[TBL] [Abstract][Full Text] [Related]
14. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
Kuk C; Kulasingam V; Gunawardana CG; Smith CR; Batruch I; Diamandis EP
Mol Cell Proteomics; 2009 Apr; 8(4):661-9. PubMed ID: 19047685
[TBL] [Abstract][Full Text] [Related]
15. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
Mikuła-Pietrasik J; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Med Oncol; 2016 Aug; 33(8):94. PubMed ID: 27431203
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.
Nagy JA; Herzberg KT; Dvorak JM; Dvorak HF
Cancer Res; 1993 Jun; 53(11):2631-43. PubMed ID: 8495427
[TBL] [Abstract][Full Text] [Related]
17. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts.
Uruski P; Mikuła-Pietrasik J; Pakuła M; Budkiewicz S; Drzewiecki M; Gaiday AN; Wierzowiecka M; Naumowicz E; Moszyński R; Tykarski A; Książek K
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921783
[TBL] [Abstract][Full Text] [Related]
18. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
19. The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome.
Greening DW; Kapp EA; Simpson RJ
Enzymes; 2017; 42():27-64. PubMed ID: 29054270
[TBL] [Abstract][Full Text] [Related]
20. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.
Monavarian M; Elhaw AT; Tang PW; Javed Z; Shonibare Z; Scalise CB; Arend R; Jolly MK; Sewell-Loftin MK; Hempel N; Mythreye K
Semin Cancer Biol; 2022 Nov; 86(Pt 2):709-719. PubMed ID: 35259492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
